Prions and Prion Disease
Many lines of evidence have argued persuasively that prions are composed largely, if not exclusively, of the scrapie isoform of prion protein (PrP). An abnormally folded isoform (PrP Sc ) of the normal, cellular prion protein (PrP C ) stimulates the conversion of PrP C into nascent PrP Sc in prion diseases (Fig. 1 ). The accumulation of PrP Sc leads to neuronal death followed by central nervous system (CNS) dysfunction. 1) The discovery that mutations in the PrP gene cause inherited prion disease in humans, 2) which is transmissible to laboratory animals, 3) and the generation of infectious prions in transgenic (Tg) mice expressing mutant PrP assert that prions are devoid of nucleic acid. 4, 5) It is be also important to mention that we identified a 55-residue peptide of a mutant prion protein that can be refolded into at least two distinct conformations. 6) When inoculated intracerebrally into the appropriate transgenic mouse host, 20 of 20 mice receiving the β-form of this peptide developed signs of CNS dysfunction at ~360 days, with neurohistologic changes that are pathognomonic of Gerstmann-Sträussler-Scheinker (GSS) disease. 7) By contrast, 8 of 8 mice receiving a non-β-form of the peptide failed to develop any neuropathologic changes more than 600 days after the peptide injections. Thus, a chemically synthesized peptide refolded into the appropriate conformation can accelerate or possibly initiate prion disease.
That the cellular isoform of PrP C interacts with PrP Sc during the formation of nascent PrP Sc was surmised from Tg mouse studies where mice expressing a Syrian hamster (SHa) PrP transgene were susceptible to SHa prions. 8) When similar Tg mice were produced expressing human (Hu) PrP, no transmission of Hu prions was found. However, mice expressing a chimeric Hu-mouse PrP (Hu-MoPrP) transgene denoted MHu2M were susceptible to Hu prions. In addition, we found that Tg mice expressing HuPrP did become susceptible to Hu prions when they were crossed with PrP-deficient (Prnp 
, the latter is a causative agent of prion disease such as Bovine Spongiform Encephalopathy (BSE, mad cow disease) and Creutzfeldt-Jakob disease (CJD). Great concern about variant CJD, which is caused by ingesting BSE-contaminated products, is also emerging and spreading over Japan since the first BSE-affected cattle was identified in September, 2001. The amino acid sequences of PrP C and PrP Sc are identical, but their conformations are rather different; PrP C is rich in the non β-sheet isoform while PrP Sc is rich in the β-sheet isoform. Our prion research focuses on further understanding such an unprecedented mechanism by identifying auxiliary factor(s) other than PrP C and PrP
Sc
. These studies also help us to develop "therapeutics and prevention methods" for prion disease. Three major trials; genetic manipulation with dominant negative mutant PrP C gene working against a hypothetical hostspecific factor, antibody therapy with anti-PrP antibodies which block PrP C -PrP Sc binding, and PrP Sc unfolding therapy with a novel-class molecular chaperone, are currently underway.
suggested that another molecule provisionally designated protein X participates in the formation of nascent PrP Sc 3) (Fig. 2) . We report the identification of the site at which protein X binds to PrP C using scrapie-infected Mo neuroblastoma cells transfected with chimeric Hu-MoPrP genes even though protein X has not yet been isolated. Substitution of a Hu residue at position 214 or 218 prevented PrP Sc formation.
9) The side chains of these residues protrude from the same surface of the C-terminal α-helix and form a discontinuous epitope with residues 167 and 171 in an adjacent loop (Fig. 3) .
Therapeutic Approaches in Prion Disease
At present, there is no accepted therapy for prion diseases, and whether the drug quinacrine will prove to be effective in treating these diseases remains to be established. 10) In addition to quinacrine, 11) other compounds that block prion replication as well as stimulate the clearance of existing prions include branched polyamines, 12) phthalocyanines and porphyrin derivatives, 13) Congo red, 14) compound 60, 15) β-breaker peptides, 16) and anti-PrP antibodies. 
Dominant Negative PrP
One compound was designed to mimic dominant negative inhibition of prion replication.
15) Dominant-negative inhibition occurs when the product of the mutant or variant allele interferes with a func- 
Fig. 2. Heterodimer Model of PrP
Sc Replication tion of the wild-type (wt) allelic protein. Naturally occurring polymorphic variants of PrP, and Q171R and E219K, which are known to render sheep and humans resistant to scrapie and CJD, 20, 21) were found to act as dominant negatives in scrapie-infected neuroblastoma cells 9, 22) (Fig. 4) . Based on these findings, we undertook studies on dominant negative PrP. To determine whether dominant-negative inhibition occurs in vivo, we produced Tg mice expressing PrP with either the Q167R or Q218K mutation alone or in combination with wt PrP. 23) Tg(MoPrP,Q167R)Prnp 0/0 mice expressing mutant PrP at levels equal to non-Tg mice remained healthy for > 550 days, indicating that inoculation with prions did not cause disease. Immunoblots of brain homogenates and histological analysis did not reveal abnormalities. Tg(MoPrP,Q167R)Prnp +/+ mice expressing both mutant and wt PrP did not exhibit neurological dysfunction, but their brains revealed low levels of PrP Sc , and sections showed numerous vacuoles and severe astrocytic gliosis at 300 days after inoculation. Both Tg(MoPrP, Q218K)Prnp 0/0 and Tg(MoPrP,Q218K)Prnp +/+ mice expressing high levels of the transgene product remained healthy for > 300 days after inoculation. Neither PrP Sc nor neuropathologic changes were found.
The inability of MoPrP(Q167R) and MoPrP(Q218K) to support prion replication raises the possibility of producing prion-resistant animals that express PrP with a single amino acid substitution. Because sheep homozygous for R at position 171 already exist, breeding populations of resistant sheep is a reasonable approach. Presumably, this was the genetic basis of Parry's scrapie eradication program in Great Britain 40 years ago. 24) A similar approach, inoculating Tg(BoPrP,Q179R) or Tg(BoPrP,Q230K) mice with bovine prions might be useful in evaluating the utility of producing prionresistant cattle. Although the introduction of a point mutation may not produce complete resistance to prion infection as disruption of the Prnp gene does, 25, 26) it may prove to be more desirable to utilize such amino acid substitutions since they are natural polymorphisms in humans and sheep.
Anti-PrP Antibodies
Reagents specifically binding either PrP conformer may interrupt prion production by inhibiting this interaction. We examined the ability of several recombinant antibody antigen-binding fragments (Fabs) to inhibit prion propagation in cultured mouse neuroblastoma cells (ScN2a) infected with PrP Sc . We showed that antibodies binding cell-surface PrP C inhibit PrP Sc formation in a dose-dependent manner 17) ( Fig. 5) . In cells treated with the most potent antibody, Fab D18, prion replication is abolished and pre-existing PrP Sc is rapidly cleared, suggesting that this antibody may cure an established infection. The potent activity of Fab D18 is associated with its ability to better recognize the total population of PrP C molecules on the cell surface, and with the location of its epitope on PrP C . Our observations support the use of antibodies in the prevention and treatment of prion diseases and identify a region of PrP C for drug targeting. For in vivo applications, Fab fragments have the disadvantage of a short half-life, and may not efficiently traverse from the peripheral circulation into the central nervous system. Whole-antibody molecules prepared from the Fabs will probably be more useful, but may require engineering to prevent the recruitment of an immunological effect to antibodycoated cells. 27) 
PrP
Sc Unfolding Biomolecules Polypeptide chains are synthesized inside cells as linear molecules and then must be folded into functional structures to perform catalysis. The failure of polypeptides to adopt their proper structure is a major threat to cell function and viability. Therefore, chaperones like HSP70s family proteins that are located in every cellular compartment, bind a wide range of proteins, and play an essential role in protein folding machinery or preventing misfolding and aggregation of newly synthesized or unfolded proteins. Recently we found and isolated novel protein unfolding activity in S. cerevisiae (N.S.H. paper in preparation). This activity is ATP-dependent and moreover does not have any specificity in vitro. Interestingly, the activity unfolded the prion protein structure even though it included a β-sheet structure, α-synulein, and amloid β-peptide (1-42) (Fig. 6) . By adding specificity to the activity, it may become a powerful tool as a novel therapeutic approach for aggregation diseases by dissolving such aggregates.
We have also explored chaperone activities related to the conformational transition of PrP C into PrP Sc in mammalian cells. We have attempted to identify activities which modulate the conformation of PrP C in mouse neuroblastoma cells using a trypsinsensitivity assay by which we identified the yeast protein unfolding activity as mentioned above. As a result, we obtained activities which modulated recombinant PrP conformation in nuclear, microsome, and cytosol fractions.
New Therapeutic Approach in Neurodegenerative Disorders
As it has been shown in past therapeutics approaches for other major human diseases such as cancer or HIV infection, a combination therapy will also be considered for neurodegenerative disorders in the near future. Even if each therapeutic approach exhibits a limited cure with considerable adverse effects, a combination of two or three approaches might be able to improve the patient's prognosis. Whether the combination of drugs and biomolecules such as low-dose quinacrine, dominant negative PrP, anti-PrP antibody, and a PrP Sc -unfolding chaperone more efficiently inhibits prion replication remains to be established. Such studies are currently underway.
